Sam Chun Dang Pharm. Co., Ltd
Financials
Valuation Metrics
Sam Chun Dang Pharm. Co., Ltd's Market Cap is ₩3.9T. At end of 2025 it was ₩5.5T. Ranked #120 of 2,436 in KR market (top 5%), #13 of 1,649 on KOSDAQ (top 0.8%), #12 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 5%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 3.92T KRW | KR#120/2,436 Sec#12/234 |
| Revenue | 246.05B KRW | KR#913/2,436 Sec#47/234 |
| Net Income | 17.66B KRW | KR#697/2,436 Sec#46/234 |
| Total Assets | 573.12B KRW | KR#680/2,436 Sec#39/234 |
| Net Assets | 394.47B KRW | KR#583/2,436 Sec#37/234 |
| Employees | 417 | KR#582/2,436 Sec#49/234 |
| Value | ||
| P/E | 222.21x | KR#1,474/2,436 Sec#101/234 |
| P/B | 9.95x | KR#2,348/2,436 Sec#210/234 |
| PEG | 0.50x | KR#666/2,436 Sec#39/234 |
| P/S | 15.95x | KR#2,317/2,436 Sec#176/234 |
| EV/EBITDA | 293.70x | KR#1,540/2,436 Sec#108/234 |
| FCF Yield | -0.93% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 4.48% | KR#1,063/2,436 Sec#80/234 |
| ROA | 3.08% | KR#943/2,436 Sec#81/234 |
| Op. Margin | 5.38% | KR#881/2,436 Sec#72/234 |
| Revenue Growth | 28.15% | KR#507/2,436 Sec#48/234 |
| Earnings Growth | 441.60% | KR#125/2,436 Sec#8/234 |
| Financial Health | ||
| Debt Ratio | 145.29% | KR#1,126/2,436 Sec#128/234 |
| Total Debt | 44.71B KRW | KR#1,025/2,436 Sec#71/234 |
| FCF | -36.35B KRW | KR#2,032/2,436 Sec#199/234 |
| Cash | 84.21B KRW | KR#520/2,436 Sec#27/234 |
| Current Ratio | 2.18x | KR#857/2,436 Sec#99/234 |
| Net Debt/EBITDA | -2.99x | KR#204/2,436 Sec#8/234 |
| Dividend | ||
| Div. Yield | 0.03% | KR#1,380/2,436 Sec#89/234 |
| Div. Growth | -75.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -14.16% | KR#1,091/2,436 Sec#82/234 |
| 1M Return | -21.82% | KR#2,243/2,436 Sec#222/234 |
| From 52W High | -86.43% | KR#2,413/2,436 Sec#233/234 |
| 1Y MDD | -89.32% | KR#2,414/2,436 Sec#232/234 |
| Trading | ||
| Volume | 240,837 shares | KR#493/2,436 Sec#49/234 |
| Foreign Own. | 5.45% | KR#729/2,436 Sec#71/234 |
| Per Share | ||
| EPS | 436 KRW | KR#962/2,436 Sec#67/234 |
| BPS | 12,740 KRW | KR#777/2,436 Sec#53/234 |
Company Info
Samchundang Pharm, established in 1943 and headquartered in Hwaseong-si, Gyeonggi-do, began as a pharmaceutical manufacturer and seller. By acquiring Optus Pharm in 2013, it became a leading specialized ophthalmic treatment company, producing prescription-based pharmaceuticals including antibiotics, circulatory disease treatments, digestive disease treatments, and eye drops. The company is actively expanding its global market presence by exporting finished pharmaceuticals to Vietnam, Hong Kong, and Singapore.